Table 1.
Patient and treatment characteristics
| All patients | Metastatic Disease |
Primary Tumor |
|
|---|---|---|---|
| No. Patients | 15 | 12 | 3 |
| Histology | |||
| Melanoma | 4 | 4 | 0 |
| NSCLC | 3 | 3 | 0 |
| Adenoid cystic | 2 | 2 | 0 |
| HNSCC | 1 | 1 | 0 |
| Chordoma | 1 | 1 | 0 |
| Anaplastic meningioma | 1 | 0 | 1 |
| CNS sarcoma | 1 | 0 | 1 |
| WHO grade II astrocytoma | 1 | 0 | 1 |
| Prior RT | 2 | 2 | 0 |
| Age (Median) | 58.7 (31–77) | 54.4 (37–77) | 50.7 (31–76) |
| <45 | 2 | 1 | 1 |
| 45–54 | 3 | 2 | 1 |
| 55–64 | 5 | 5 | 0 |
| 65–74 | 3 | 3 | 0 |
| 75+ | 2 | 1 | 1 |
| Gender | |||
| Male | 12 | 9 | 3 |
| Female | 3 | 3 | 0 |
| Race | |||
| Caucasian | 10 | 9 | 1 |
| African-American | 3 | 3 | 0 |
| Asian-American | 2 | 0 | 2 |
| WHO Performance | |||
| 0 | 3 | 2 | 1 |
| 1 | 12 | 10 | 2 |
| Target | |||
| Whole brain | 9 | 9 | 0 |
| Partial brain | 6 | 3 | 3 |
| RT Dose (median, Gy) | 37.5 (14–70) | 37.5 (14–59.4) | 60.0 (50.4–70) |
| RT dose per fraction | |||
| 1.8 Gy | 2 | 1 | 1 |
| 2.0 Gy | 2 | 0 | 2 |
| 2.5 Gy | 8 | 8 | 0 |
| 3.0 Gy | 1 | 1 | 0 |
| 3.5 Gy | 2 | 2 | 0 |
| Total Dose | |||
| <25 Gy | 1 | 1 | 0 |
| 25–30 Gy | 2 | 2 | 0 |
| 35–45 Gy | 7 | 7 | 0 |
| >45 Gy | 5 | 2 | 3 |
| Median weeks of sunitinib treatment (range) |
5 (0.6–10.8) | 4.7 (0.6–10.8) | 6.4 (2.6–8.8) |